Carella, A M <br/><br/>
Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias?  [electronic resource] 

 -  Annals of hematology  Jun 2010 
 - 531-3 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1432-0584 
<br/><br/><label>Standard No.: </label>10.1007/s00277-010-0907-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Drug Administration Schedule<br/>Humans<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Models, Theoretical<br/>Neoadjuvant Therapy<br/>Protein Kinase Inhibitors--administration & dosage<br/>Proto-Oncogene Proteins c-abl--antagonists & inhibitors<br/>Risk Factors